Compare DexCom, Inc. (DXCM) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lockheed Martin Corporation — how do they compare? DexCom, Inc. trades at $77.95 (market cap $28.06B), while Lockheed Martin Corporation trades at $516.4 (market cap $118.62B). The key difference: Lockheed Martin Corporation is far larger — about 4.2× DexCom, Inc.'s market cap, and Lockheed Martin Corporation pays a 2.68% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LMT | |
|---|---|---|
Market Cap | $28.06B | $118.62B |
Sector | Health | Industrials |
52-Week High | $89.53 | $676.70 |
52-Week Low | $54.84 | $410.74 |
Enterprise Value | $27.03B | $137.42B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Lockheed Martin (LMT) trades at $515.75, up 0.15% on the day, with a bearish technical signal but strong analyst support. The stock shows robust fundamentals including a $75.05B revenue in 2025, a 6.38% net income margin, and a high ROE of 67.64%. Recent news highlights expansion into European venture capital and a $194B backlog, signaling long-term demand. However, earnings misses in Q4 2025 and Q1 2026 pose near-term execution challenges amid escalating defense spending trends.
The outlook for LMT is positive due to strong defense budgets and a massive backlog, but risks include earnings volatility and high debt levels. With 57% of analysts rating it Buy and a consensus price target of $614, the stock offers potential upside, though investors should monitor margin improvements and geopolitical developments affecting defense contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
